Pfizer Discontinues Clinical Trials for PF-3512676 Combined With Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer
Posted on: Wednesday, 20 June 2007, 15:05 CDT
Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy. This includes two Phase 3 clinical trials and two Phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical Group (NASDAQ: COLY) in 2005.
A scheduled interim analysis of the Phase 3 clinical trials by an independent Data Safety Monitoring Committee (DSMC) showed that there was no evidence that PF-3512676 produced additional clinical efficacy over that achieved with the standard cytotoxic chemotherapy regimen alone. The DSMC concluded that the risk-benefit profile did not justify continuation of the trials. Pfizer agrees with the findings of the DSMC and is discontinuing the related clinical trials.
Following receipt of these results from the DSMC, Pfizer immediately began outreach to worldwide regulatory authorities and clinical trial investigators.
"We are communicating these results to patients and the scientific and medical community," said Dr. Charles Baum, vice president of Pfizer's Research and Development. "While these results show the challenge of bringing new therapies to patients with cancer, Pfizer remains committed to advancing our broad and diverse oncology programs which include over two hundred clinical trials of sixteen new medicines in clinical studies in immunotherapy, signal transduction inhibition and angiogenesis inhibition."
Source: Business Wire
Related Articles
- Lexicon Pharmaceuticals' Drug Candidate for Irritable Bowel Syndrome Completes Phase 1 Clinical Trial Showing Positive Results
- ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
- Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
- MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of Its MOR103 Program
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Clinical Data Announces Positive Results From Phase III Pivotal Trial of Vilazodone for Depression
- Curis Provides Update on Basal Cell Carcinoma Phase I Clinical Trial; Parties Determine to Halt Phase I Trial
- AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status; Data From the Phase I/II Accepted for Oral Platform Presentation at ICAR
- Lipitor's Safety Again Confirmed in Extensive Analysis of 49 Clinical Trials, Pfizer Says
- Clinical Trial Demonstrates Positive Results for St. Jude Medical Device Treating Coronary Bypass Graft Blockages
 |
 |
User Comments (0)
RSS Feeds